Citi downgrades Illumina stock rating to Sell on concerns over 2H outlook

Citi downgraded Illumina (ILMN) to Sell from Neutral, lowering its price target to $80 from $85, citing significant concerns over the gene sequencing company's second-half outlook, particularly challenges in consumables ramp due to academic and China conditions, and the potential for a third guidance reduction this year. This bearish assessment comes as Illumina recently announced the strategic acquisition of SomaLogic for up to $425 million, aiming to enhance its proteomics market presence and achieve profitability by 2027. Meanwhile, Bernstein notes cautious optimism for a recovery in the broader Life Science Tools & Diagnostics sector, though consistent financial results are still needed to fully reassure investors.

Analysis

Illumina (ILMN) is facing significant near-term headwinds, underscored by a downgrade from Citi to Sell with a price target reduction to $80 from $85. The downgrade is predicated on concerns over the company's second-half outlook, specifically a challenged consumables ramp-up attributed to a soft academic environment and difficult conditions in China. Citi highlights a critical risk of a potential third earnings per share guidance cut this year, noting that even maintaining current guidance could be perceived negatively by the market as it would leave performance concerns unaddressed. This operational uncertainty contrasts with Illumina's long-term strategic initiatives, including the acquisition of Standard BioTools' SomaLogic business for up to $425 million. This deal is intended to bolster Illumina's presence in the proteomics market, with the acquired unit projected to reach profitability by 2027. For Standard BioTools (LAB), the divestiture is a strategic positive, streamlining operations and securing a cash position of at least $550 million post-closure. The broader Life Science Tools & Diagnostics sector, according to Bernstein, may be poised for a recovery, but the firm remains cautious, emphasizing the need for consistent financial results to restore investor confidence, a benchmark Illumina is currently failing to meet.

Key Decisions for Investors

• Given the Citi downgrade to Sell and the explicit warning of a potential third guidance cut, investors should exercise extreme caution with Illumina (ILMN) and scrutinize its upcoming second-quarter results for any revision to its second-half outlook.
• Long-term investors in Illumina must weigh the significant near-term execution risks and stock underperformance against the strategic potential of the SomaLogic acquisition, which aims to build a footprint in proteomics but is not expected to be profitable until 2027.
• The sale of SomaLogic is a clear positive for Standard BioTools (LAB), as it significantly strengthens the balance sheet and creates a clear path to adjusted EBITDA break-even, warranting a positive reassessment of its financial stability.
• While the broader sector may be showing signs of a bottom according to Bernstein, investors should remain selective and prioritize companies demonstrating stable execution over those like Illumina that are currently facing significant company-specific headwinds.